Telehealth Obesity Platforms Become Care Orchestrators

This partnership wave turned GLP-1 telehealth from a gray market supply arbitrage into a cleaner distribution business. During shortages, Ro won by packaging intake, prescribing, compounding, and fulfillment in one app. Once the shortage exception ended, that advantage flipped. Drug makers had product and pricing power but no trusted consumer funnel, while Ro had demand, clinicians, and checkout flow but needed legal branded inventory to keep its obesity business running and growing.

• Before branded partnerships, the biggest value was convenience for people denied coverage. Ro could route someone to insurance, cash pay, or compounded semaglutide, and the compounded path carried roughly 80% gross margins because the platform controlled the full transaction from consult to refill.
  1 sacra
• After compounding tightened, manufacturers effectively rented Ro's front door. Ro kept the patient experience inside its app, but the prescription and payment were pushed into NovoCare or LillyDirect backed fulfillment. That let Ro offer branded Wegovy at $499 instead of the $1,349 list price without owning the drug supply itself.
  1 sacra 2 sacra
• This also erased drug sourcing as a moat. Novo Nordisk standardized the same $499 branded Wegovy access across Ro, Hims & Hers, and LifeMD, so competition moved back to who can retain patients with labs, titration, insurance help, and coaching, not who can find boxes of medicine.
  2 sacra

The next step is that telehealth obesity players look less like pharmacies and more like care orchestration layers sitting on top of manufacturer supply. If branded access stays standardized and low priced, the winners will be the companies that can prove better adherence, lower dropout, and stronger employer and payer outcomes with the same underlying drugs.